CY1121558T1 - Διλειτουργικα πολυπεπτιδια - Google Patents

Διλειτουργικα πολυπεπτιδια

Info

Publication number
CY1121558T1
CY1121558T1 CY20191100410T CY191100410T CY1121558T1 CY 1121558 T1 CY1121558 T1 CY 1121558T1 CY 20191100410 T CY20191100410 T CY 20191100410T CY 191100410 T CY191100410 T CY 191100410T CY 1121558 T1 CY1121558 T1 CY 1121558T1
Authority
CY
Cyprus
Prior art keywords
peptide
antibody
moiety
binding
mhc
Prior art date
Application number
CY20191100410T
Other languages
English (en)
Inventor
Bent Karsten Jakobsen
Annelise Brigitte Vuidepot
Yi Li
Original Assignee
Immunocore Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40834242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121558(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunocore Ltd. filed Critical Immunocore Ltd.
Publication of CY1121558T1 publication Critical patent/CY1121558T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

Διλειτουργικό πολυπεπτίδιο το οποίο αποτελείται από έναν ειδικό εταίρο πρόσδεσης για έναν επίτοπο πεπτιδίου-MHC, όπως ένα αντίσωμα ή ένας υποδοχέας Τ κυττάρων ("TCR"), και έναν άνοσο τελεστή, όπως ένα αντίσωμα ή μια κυτοκίνη, με το τμήμα άνοσου τελεστή να συνδέεται στο Ν-άκρο του τμήματος πρόσδεσης πεπτιδίου-MHC.
CY20191100410T 2009-05-20 2019-04-12 Διλειτουργικα πολυπεπτιδια CY1121558T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0908613.3A GB0908613D0 (en) 2009-05-20 2009-05-20 T Cell Reseptors
EP10720803.5A EP2432802B1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
PCT/GB2010/000988 WO2010133828A1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides

Publications (1)

Publication Number Publication Date
CY1121558T1 true CY1121558T1 (el) 2020-05-29

Family

ID=40834242

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20161101365T CY1118405T1 (el) 2009-05-20 2016-12-30 Διλειτουργικα πολυπεπτιδια
CY20181100507T CY1120439T1 (el) 2009-05-20 2018-05-04 Διλειτουργικα πολυπεπτιδια
CY20191100410T CY1121558T1 (el) 2009-05-20 2019-04-12 Διλειτουργικα πολυπεπτιδια

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20161101365T CY1118405T1 (el) 2009-05-20 2016-12-30 Διλειτουργικα πολυπεπτιδια
CY20181100507T CY1120439T1 (el) 2009-05-20 2018-05-04 Διλειτουργικα πολυπεπτιδια

Country Status (21)

Country Link
US (6) US10130721B2 (el)
EP (3) EP3112377B1 (el)
JP (4) JP5667171B2 (el)
CN (1) CN102439034B (el)
AU (1) AU2010250951B2 (el)
BR (1) BRPI1013029A2 (el)
CA (2) CA2762604C (el)
CY (3) CY1118405T1 (el)
DK (3) DK2432802T3 (el)
EA (1) EA020841B1 (el)
ES (3) ES2608653T3 (el)
GB (1) GB0908613D0 (el)
HR (3) HRP20170086T1 (el)
HU (3) HUE043245T2 (el)
LT (3) LT3112377T (el)
MX (1) MX340168B (el)
PL (3) PL3112377T3 (el)
PT (3) PT3112377T (el)
SI (3) SI3112376T1 (el)
TR (2) TR201905437T4 (el)
WO (1) WO2010133828A1 (el)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
US9133244B2 (en) 2011-01-18 2015-09-15 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
CA2848209C (en) * 2011-09-15 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
WO2013048243A1 (en) * 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
BR112014010532A2 (pt) 2011-11-03 2017-04-18 Tolera Therapeutics Inc anticorpo e métodos para inibição seletiva de respostas de célula-t
SG10201705698PA (en) 2012-01-13 2017-08-30 Apo-T B V Aberrant Cell-Restricted Immunoglobulins Provided With A Toxic Moiety
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
WO2015136072A1 (en) 2014-03-14 2015-09-17 Immunocore Limited Tcr libraries
US10526391B2 (en) 2014-07-22 2020-01-07 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
CN107223133B (zh) 2014-11-07 2021-01-29 广东香雪精准医疗技术有限公司 一种可溶的异质二聚t细胞受体及其制法和应用
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516275D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516274D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516270D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516265D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516269D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
CN108350032A (zh) 2015-10-09 2018-07-31 比奥尼斯有限责任公司 调节γC-细胞因子活性
GB201520558D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520567D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (en) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201520570D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520539D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201604468D0 (en) 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520575D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520579D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2018083505A1 (en) 2016-11-07 2018-05-11 Immunocore Limited Peptides
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520544D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520536D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520557D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520542D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520548D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520595D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520589D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520562D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520543D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607535D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
DK3430037T3 (da) * 2016-03-16 2022-11-21 Immatics Biotechnologies Gmbh Transficerede t-celler og t-cellereceptorer til anvendelse i immunterapi mod cancere
GB201604953D0 (en) 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
HUE059159T2 (hu) 2016-04-08 2022-10-28 Immunocore Ltd T-sejt-receptorok
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
AU2017273147A1 (en) 2016-06-02 2019-01-03 Immunocore Limited Dosing regimen for GP100-specific TCR - anti-CD3 SCFV fusion protein
EP3532078A4 (en) * 2016-10-31 2020-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. ARTIFICIAL ANTIGEN PRESENT CELLS USED FOR THE EXPANSION OF IMMUNE CELLS FOR IMMUNOTHERAPY
CN108203459A (zh) * 2016-12-19 2018-06-26 广东香雪精准医疗技术有限公司 源自于prame的肿瘤抗原短肽
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
CN112424230A (zh) 2018-05-14 2021-02-26 英美偌科有限公司 双功能结合多肽
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
AU2020208110A1 (en) * 2019-01-14 2021-07-15 Nanjing Legend Biotech Co., Ltd. Chimeric receptor polypeptides and uses thereof
CA3126611A1 (en) 2019-01-17 2020-07-23 Immunocore Limited Formulations of soluble t cell receptor(tcr) and single chain fragment variable (scfv) bispecific proteins
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
JP2022519649A (ja) 2019-02-08 2022-03-24 ジェネンテック， インコーポレイテッド がんの診断および治療方法
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
CN113906140A (zh) 2019-03-18 2022-01-07 路德维格癌症研究院 A2/ny-eso-1特异性t细胞受体及其用途
GB201904328D0 (en) 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
GB202005779D0 (en) 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
GB202006629D0 (en) 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
WO2023288203A2 (en) 2021-07-12 2023-01-19 Ludwig Institute For Cancer Research Ltd T cell receptors specific for tumor-associated antigens and methods of use thereof
CN115724988B (zh) * 2021-08-26 2023-11-17 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子
EP4198052A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers
WO2023156663A1 (en) 2022-02-20 2023-08-24 Immunocore Limited Hiv-specific binding molecules and tcr
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038198A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024067821A1 (zh) * 2022-09-30 2024-04-04 瑅安生物医药（杭州）有限公司 一种修饰细胞及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
DK1066380T3 (da) * 1998-05-19 2002-01-28 Avidex Ltd Opløselig T-cellereceptor
JP4467188B2 (ja) * 1998-10-21 2010-05-26 アルター・バイオサイエンス・コーポレーション 多重特異的結合分子とその使用
JP2004501364A (ja) 2000-05-25 2004-01-15 スノル・モレキュラー・コーポレーション Ｔ−細胞レセプター相互作用のモジュレーション
WO2001093913A2 (en) * 2000-06-05 2001-12-13 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
JP2005533486A (ja) * 2002-02-20 2005-11-10 ダイアックス、コープ Ｍｈｃ−ペプチド複合体結合リガンド
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
NZ550810A (en) 2004-05-19 2009-05-31 Immunocore Ltd High affinity NY-ESO T cell receptor
AU2005247950B2 (en) * 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090042285A1 (en) 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof
EP1763365B1 (en) 2004-06-09 2016-08-10 Technion Research And Development Foundation, Ltd. Antibodies for selective apoptosis of cells
JP2008514685A (ja) * 2004-10-01 2008-05-08 メディジーン リミテッド 治療剤に連結した、非天然型ジスルフィド鎖間結合を含有するｔ細胞レセプター
DK1976880T3 (en) * 2005-12-21 2016-09-26 Amgen Res (Munich) Gmbh Pharmaceutical compositions with resistance to soluble cea
EP1981532A4 (en) * 2005-12-21 2010-06-30 Medimmune Llc EPHA2 MOLECULES AND USES THEREOF
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
GB0816096D0 (en) 2008-09-04 2008-10-15 Medigene Ltd Diabetes t cell receptors
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
MX340168B (es) 2016-06-29
LT3112377T (lt) 2018-05-25
US20190231896A1 (en) 2019-08-01
JP5667171B2 (ja) 2015-02-12
GB0908613D0 (en) 2009-06-24
US20230241238A1 (en) 2023-08-03
CA2968393C (en) 2019-07-23
US20190231895A1 (en) 2019-08-01
EA201101660A1 (ru) 2012-05-30
US20120190828A1 (en) 2012-07-26
CN102439034A (zh) 2012-05-02
SI3112376T1 (sl) 2019-08-30
AU2010250951B2 (en) 2015-04-30
DK3112376T3 (en) 2019-04-29
ES2608653T3 (es) 2017-04-12
ES2672095T3 (es) 2018-06-12
EP3112377B1 (en) 2018-04-18
JP2012527439A (ja) 2012-11-08
JP2019172678A (ja) 2019-10-10
CY1120439T1 (el) 2019-07-10
EA201101660A8 (ru) 2014-09-30
DK3112377T3 (en) 2018-07-30
US10420846B2 (en) 2019-09-24
EA020841B1 (ru) 2015-02-27
ES2721058T3 (es) 2019-07-26
SI3112377T1 (en) 2018-06-29
US10130721B2 (en) 2018-11-20
CA2968393A1 (en) 2010-11-25
BRPI1013029A2 (pt) 2016-04-05
HUE032929T2 (hu) 2017-11-28
US20190275165A1 (en) 2019-09-12
HRP20180757T1 (hr) 2018-07-27
DK2432802T3 (en) 2017-02-13
CY1118405T1 (el) 2017-06-28
CN102439034B (zh) 2015-01-28
MX2011012184A (es) 2012-03-26
CA2762604A1 (en) 2010-11-25
PT3112376T (pt) 2019-05-20
CA2762604C (en) 2018-01-16
PT3112377T (pt) 2018-07-13
PL2432802T3 (pl) 2017-07-31
US10576162B2 (en) 2020-03-03
EP2432802A1 (en) 2012-03-28
JP2015096527A (ja) 2015-05-21
EP2432802B1 (en) 2016-11-02
EP3112376A2 (en) 2017-01-04
PL3112376T3 (pl) 2019-07-31
SI2432802T1 (sl) 2017-01-31
HRP20190674T1 (hr) 2019-08-09
HRP20170086T1 (hr) 2017-06-02
JP2017110019A (ja) 2017-06-22
EP3112377A1 (en) 2017-01-04
EP3112376A3 (en) 2017-03-29
HUE043245T2 (hu) 2019-08-28
EP3112376B1 (en) 2019-01-23
PT2432802T (pt) 2017-02-13
US20190247512A1 (en) 2019-08-15
LT2432802T (lt) 2017-01-10
TR201809945T4 (tr) 2018-08-27
PL3112377T3 (pl) 2018-10-31
AU2010250951A1 (en) 2011-12-08
LT3112376T (lt) 2019-05-10
TR201905437T4 (tr) 2019-05-21
WO2010133828A1 (en) 2010-11-25
US10517960B2 (en) 2019-12-31
HUE038342T2 (hu) 2018-10-29

Similar Documents

Publication Publication Date Title
CY1121558T1 (el) Διλειτουργικα πολυπεπτιδια
BR112019014986A8 (pt) Anticorpo que alveja bcma e uso do mesmo
CY1122720T1 (el) Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii
ECSP19000282A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
CY1122509T1 (el) Πολυπεπτιδια χιμαιρικου παραγοντα viii και χρησεις αυτων
CY1124835T1 (el) Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας
PH12018500861A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
CL2018002762A1 (es) Receptores de antígeno quimérico y células t y métodos de uso.
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
CY1121767T1 (el) Πολυπεπτιδια που περιεχουν μη γαυκοζυλιωμενη fc
CY1120328T1 (el) Συνθεση εμβολιου περιεχουσα συνθετικο ανοσοενισχυτικο
MX2020010241A (es) Composiciones de inmunoterapia celular y usos de las mismas.
MX2020006409A (es) Moléculas de unión al antígeno específicas para ror1.
MX2022015399A (es) Conjugados de superficie celular y composiciones y metodos celulares relacionados.
CY1116584T1 (el) Ανθρωπινα αυτοαντισωματα αντι-αλφα-συνουκλεϊνης
DK2142570T3 (da) Anti-EpCam-antistof og anvendelser deraf
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2021009274A (es) Moleculas de union a multiples dominios.
JOP20220150A1 (ar) مواد وطرق للاستهداف البيولوجي في الجسم الحي
WO2011137243A3 (en) Fluorescent fusion polypeptides and methods of use
CY1120686T1 (el) Αντισωματα ειδικα για το ανθρωπινο πολυπεπτιδιο αμυλοειδους των νησιδιων (ηιαρρ) και χρησεις αυτων